Pharmaceutical composition for sustained release delivery of buprenorphine
AssigneeForesee Pharmaceuticals Co., Ltd.
InventorsYuhua LI, MingHsin LI, Chen-Chang LEE, Chia-Ying YANG, Chih-Ying LIN
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.
Claims14
A pharmaceutical composition comprising 1) at least 1 wt % of buprenorphine or its salt thereof;
- and 2) a pharmaceutically acceptable solvent selected from the group consisting of ethanol, benzyl alcohol (BA), benzyl benzoate (BB), propylene glycol (PG), glycol, glycofurol, polyethylene glycol 300 (PEG300), and polyethylene glycol 400 (PEG400), and a combination of two or more thereof.
-60. (canceled)
A pharmaceutical composition comprising 1) at least 1 wt % of buprenorphine or its salt thereof;
- 2) a pharmaceutically acceptable solvent selected from the group consisting of ethanol, benzyl alcohol (BA), benzyl benzoate (BB), propylene glycol (PG), glycol, N-methyl pyrrolidone (NMP), glycofurol, dimethylacetamide (DMAc), dimethylsulfoxide (DMSO), polyethylene glycol 300 (PEG300), and polyethylene glycol 400 (PEG400), and a combination of two or more thereof;
- and 3) a fatty acid.
A pharmaceutical composition comprising 1) at least 1 wt % of buprenorphine or its salt thereof;
- 2) a pharmaceutically acceptable solvent selected from the group consisting of ethanol, benzyl alcohol (BA), benzyl benzoate (BB), propylene glycol (PG), glycol, N-methyl pyrrolidone (NMP), glycofurol, dimethylacetamide (DMAc), dimethylsulfoxide (DMSO), polyethylene glycol 300 (PEG300), and polyethylene glycol 400 (PEG400), and a combination of two or more thereof;
- 3) a fatty acid;
- and 4) a stabilizer.
Dependencies are inferred from the claim text.